Related Experiment Video
Updated: Aug 6, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Insulin therapy in patients with severe hypertriglyceridemia]
Héctor Eloy Tamez-Pérez1, Ramón Sáenz-Gallegos, Karina Hernández-Rodríguez
1Departamento de Endocrinología, Divisíon de Medicina Interna, Hospital de Especialidades 25, Instituto Mexicano del Seguor Social, Monterray, Nuevo Léon. hectoreloytamez@aol.com
Revista Medica Del Instituto Mexicano Del Seguro Social
|July 28, 2006
Summary
Intravenous insulin effectively and safely lowers severe hypertriglyceridemia (triglyceride levels > 1000 mg/dL) in patients, including those with diabetes or on anti-retroviral drugs. This treatment rapidly reduces triglyceride levels, offering a safe therapeutic option.
Area of Science:
- Endocrinology
- Metabolic Disorders
Context:
- Severe hypertriglyceridemia (triglyceride levels > 1000 mg/dL) poses significant health risks, including acute pancreatitis.
- This condition can be exacerbated by diabetes and certain medications like anti-retroviral drugs.
Purpose:
- To evaluate the efficacy and safety of intravenous insulin infusion for managing severe hypertriglyceridemia.
Summary:
- Seven patients with severe hypertriglyceridemia received intravenous insulin infusion (0.05-2 U/kg/day).
- Within 2.5 days, triglyceride levels decreased to below 400 mg/dL in all patients.
- The treatment was well-tolerated, with no reported complications. Long-term management involved basal insulin, fibrates, and lifestyle modifications.
Impact:
- Intravenous insulin therapy is a safe and effective treatment for severe hypertriglyceridemia in both diabetic and non-diabetic patients.
- This approach offers a rapid and well-tolerated method to manage dangerously high triglyceride levels.
- Highlights the potential of insulin as a critical intervention in metabolic emergencies.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...